Nexus announces availability of Arsenic Trioxide Injection in the US

Nexus Pharmaceuticals announced today the immediate availability in the United States for Arsenic Trioxide Injection. Nexus Pharmaceuticals' Arsenic Trioxide Injection is available as 10mg per 10mL vial for injection.

The product is the AP rated generic alternative of TRISENOX® indicated for relapsed or refractory acute promyelocytic leukemia.

"The approval of generic Arsenic Trioxide injection continues to show Nexus's commitment in providing access to affordable critical-need generic injectables," said Chief Commercial Officer Omair Ahmed. "Collectively, as drug manufacturers and healthcare providers, we have a commitment to patients to ensure they are receiving affordable drugs they need, when they need them, which is why we make it our highest priority to be a reliable partner in supplying critical need drugs."

Advertisement

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News-Medical.Net.
Post a new comment
Post
You might also like... ×
Research advances offer hope for patient-tailored AML treatment